MYB and cancer: Using thresholds of the PRIME score based on a z-score, which is calculated on a TF model-specific empirical distribution, by scoring that model on 20000 variants from TCGA; we found relatively few mutations, with only 0.1%– 1.2% high impact mutations with PRIME>0.3 (comparable to the MYB-TAL1 mutation) per cancer genome, on average.